Ephemeranthol A

Ephemeranthol A 是一种具有抗癌和抗炎活性的菲类化合物,它通过抑制 NF-κB 和 MAPK 信号通路在巨噬细胞中发挥显著的抗炎作用,并通过抑制 FAK/Akt 信号和 EMT 过程诱导肺癌细胞凋亡 (apoptosis) 和抑制转移,可用于急慢性炎症疾病和非小细胞肺癌的研究。
产品编号: MS-E32300 CAS No.: 135545-86-7 分子式: C16H16O4 分子量: 272.30
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Ephemeranthol A 是一种具有抗癌和抗炎活性的菲类化合物,它通过抑制 NF-κB 和 MAPK 信号通路在巨噬细胞中发挥显著的抗炎作用,并通过抑制 FAK/Akt 信号和 EMT 过程诱导肺癌细胞凋亡 (apoptosis) 和抑制转移,可用于急慢性炎症疾病和非小细胞肺癌的研究。

生物实验数据

生物活性 Ephemeranthol A is a phenanthrene compound with anticancer and anti-inflammatory activities that exerts significant anti-inflammatory effects in macrophages by inhibiting the NF-κB and MAPK signaling pathways, and induces apoptosis and inhibits metastasis in lung cancer cells by suppressing FAK/Akt signaling and the EMT process, making it useful for research on acute and chronic inflammatory diseases and non-small cell lung cancer.
IC50 & Target

NF-κB

 

iNOS

 

COX-2

 

IL-1β

 

IL-6

 

体外研究
(In Vitro)

Ephemeranthol A (6.25-50 μg/mL; 25 h) 在浓度 ≤ 25 μg/mL 时对 Raw 264.7 细胞无细胞毒性,但在 50 μg/mL 浓度下会降低细胞活力。
Ephemeranthol A (6.25-50 μg/mL; 7-25 h) 强效抑制 Raw 264.7 细胞中 LPS 诱导的 NO、iNOS、COX-2、TNF-α、IL-6 和 IL-1β 生成。
Ephemeranthol A (25 μg/mL; 1.5-2 h) 可阻断 Raw 264.7 细胞中 LPS 诱导的 IκB 降解,抑制 NF-κB 亚基 p50 和 p65 的核转位。
Ephemeranthol A (6.25-25 μg/mL; 1 h) 可抑制 Raw 264.7 细胞中 LPS 诱导的 p38 和 JNK 磷酸化。
Ephemeranthol A (5-200 μM; 24-48 h) 以浓度和时间依赖的方式降低人非小细胞肺癌 H460 细胞的活力,其 24 h 时的 IC50 > 200 μM,48 h 时的 IC50 为 150.5 μM。
Ephemeranthol A (10-100 μM; 24 h) 以浓度依赖的方式诱导人非小细胞肺癌 H460 细胞发生凋亡。
Ephemeranthol A (50-100 μM; 48 h) 可通过降低 Bcl-2 水平并激活 caspase-9、caspase-3 和 PARP,在 48 h 时诱导人非小细胞肺癌 H460 细胞发生细胞凋亡。
Ephemeranthol A (50-100 μM; 48 h) 可在 48 h 时抑制人非小细胞肺癌 H460 细胞中 FAK-Akt 信号通路的激活。
Ephemeranthol A (5-50 μM; 48 h) 可抑制人非小细胞肺癌 H460 细胞的锚定非依赖性生长。
Ephemeranthol A (10-100 μM; 24-48 h) 抑制人非小细胞肺癌 H460 细胞的迁移。
Ephemeranthol A (5-100 μM; 24-48 h) 可抑制人非小细胞肺癌 H460 细胞的上皮间质转化,诱导上皮形态改变。

Western Blot Analysis

Cell Line: Raw 264.7 murine macrophage cells
Concentration: 25 μg/mL
Incubation Time: 1 h pre-incubation; 6 h LPS stimulation
Result: Reduced LPS-induced iNOS protein production in Raw 264.7 cells.\n
Reduced LPS-induced COX-2 protein production in Raw 264.7 cells.

RT-PCR

Cell Line: Raw 264.7 murine macrophage cells
Concentration: 25 μg/mL
Incubation Time: 1 h pre-incubation; 6 h LPS stimulation
Result: Significantly decreased LPS-induced mRNA levels of TNF-α, IL-6, and IL-1β.
Reduced TNF-α and IL-6 mRNA levels to the level of the unstimulated control.

ELISA Assay

Cell Line: Raw 264.7 murine macrophage cells
Concentration: 25 μg/mL
Incubation Time: 1 h pre-incubation; 24 h LPS stimulation
Result: Significantly inhibited LPS-induced production of TNF-α, IL-6, and IL-1β protein in Raw 264.7 cells.

Western Blot Analysis

Cell Line: Raw 264.7 murine macrophage cells
Concentration: 25 μg/mL
Incubation Time: 1 h pre-incubation; 30 min or 1 h LPS stimulation
Result: Blocked LPS-induced IκB degradation at 30 min post-stimulation.
Sustained the inhibitory effect until 1 h post-stimulation.\n
Inhibited LPS-induced translocation of p50 and p65 into the nucleus at 30 min post-stimulation.

Western Blot Analysis

Cell Line: Raw 264.7 murine macrophage cells
Concentration: 25 μg/mL (p38, JNK phosphorylation at 10/20 min); 6.25, 12.5 and 25 μg/mL (p38 phosphorylation at 10 min)
Incubation Time: 1 h pre-incubation; 10 min or 20 min LPS stimulation (p38, JNK phosphorylation); 1 h pre-incubation, 10 min LPS stimulation (p38 phosphorylation dose-response)
Result: Reduced LPS-induced phosphorylation of p38 and JNK at 10 min and 20 min post-stimulation.
Sustained the inhibitory effect on JNK phosphorylation for 20 min.
Induced a dose-dependent reduction in LPS-induced p38 phosphorylation at 6.25, 12.5, and 25 μg/mL.

Cell Cytotoxicity Assay

Cell Line: human non-small cell lung cancer H460 cells
Concentration: 5, 10, 50, 100 and 200 μM
Incubation Time: 24 h; 48 h
Result: Exhibited non-toxic to slightly toxic effects at concentrations ≤ 50 μM.
Caused significant cell viability reduction at 100 and 200 μM at both 24 and 48 h.
Reached an IC50 of > 200 μM at 24 h and 150.5 μM at 48 h.

Apoptosis Analysis

Cell Line: human non-small cell lung cancer H460 cells
Concentration: 10, 50 and 100 μM
Incubation Time: 24 h
Result: Induced concentration-dependent increases in apoptotic cell number.
Resulted in a significant increase to ~17% apoptotic nuclei at 100 μM.
Kept necrotic cell numbers minimal across all concentrations.

Western Blot Analysis

Cell Line: human non-small cell lung cancer H460 cells
Concentration: 50, 100 μM
Incubation Time: 48 h
Result: Increased cleaved PARP levels 1.98-fold (50 μM) and 2.33-fold (100 μM).
Increased cleaved caspase-9 levels 1.52-fold (50 μM) and 1.73-fold (100 μM).
Increased cleaved caspase-3 levels 4.78-fold (100 μM).
Reduced Bcl-2 levels to 0.63-fold (100 μM).
Showed no significant effects on Mcl-1 or Bax levels.
Reduced the p-FAK/total FAK ratio to 0.82-fold (50 μM) and 0.59-fold (100 μM).
Reduced the p-Akt/total Akt ratio to 0.52-fold (100 μM).
Kept total FAK and total Akt levels largely unchanged.

Cell Migration Assay

Cell Line: human non-small cell lung cancer H460 cells
Concentration: 10, 50 and 100 μM
Incubation Time: 24 h; 48 h
Result: Showed no significant effect on wound closure at 24 h.
Reduced wound closure to 33.77% (50 μM) and 25.06% (100 μM) at 48 h, compared to untreated control wound closure of 38.40%.

化学信息

分子量 272.30
分子式 C16H16O4
CAS No. 135545-86-7

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础